

Contribution to Kenerzeo of Kenercy's entire participation and acquisition of Danske Bank Asset Management's participation in Groupe Berkem's share capital in view of a simplified tender offer project

Blanquefort (France), July 31, 2024, at 06:00 pm CEST - Groupe Berkem (ISIN code: FR00140069V2 – ticker: ALKEM) (the « **Group** »), a leading player in bio-based chemistry, following [the Company's publication on July 18, 2024](#), announces:

- The final completion of the contribution-in-kind by Kenercy¹ of 100% of its Groupe Berkem shares to Kenerzeo²;
- In accordance with the reciprocal purchase and sale agreements signed on July 17, 2024, the off-market cash sale by Danske Bank Asset Management of 1,322,931 Groupe Berkem shares, representing 7.46% of Groupe Berkem's share capital, at a price of €3.10 per share, to Kenerzeo. Settlement-delivery of the shares sold in cash will take place no later than August 2, 2024 ;
- The issue by Kenerzeo of the first tranches of convertible bonds subscribed by funds managed by Eurazeo for an initial amount of 10.5 million euros and the entry into force of a shareholders' agreement between Kenercy and Eurazeo.

On August 2, 2024, Kenerzeo will hold 75.38% of Groupe Berkem's share capital.

Early October 2024, Kenerzeo will file on a mandatory basis, a simplified tender offer project for the remaining outstanding shares of Groupe Berkem, at a price of €3.10 per share. Kenerzeo intends to implement a mandatory squeeze-out at the end of the tender offer if the Company's minority shareholders who have not tendered their shares to the offer represent less than 10% of Groupe Berkem's share capital and voting rights.

ABOUT GROUPE BERKEM

Founded in 1993 by Olivier Fahy, Chairman and Chief Executive Officer, Groupe Berkem is a leading force in the bio-based chemicals market. Its mission is to advance the environmental transition of companies producing the chemicals used in everyday life (Construction & Materials, Health, Beauty & Nutrition, Hygiene & Protection, and Industry). By harnessing its expertise in both plant extraction and innovative formulations, Groupe Berkem has developed bio-based boosters—unique high-quality bio-based solutions augmenting the performance of synthetic molecules. Groupe Berkem achieved revenue of €51.9 million in 2023. The Group has almost 250 employees working at its head office (Blanquefort, Gironde) and 5 production facilities in Gardonne (Dordogne), La Teste-de-Buch (Gironde), Chartres (Eure-et-Loir), Tonneins (Lot-et-Garonne) and Valence (Spain).

Groupe Berkem has been listed on Euronext Growth Paris since December 2021 (ISIN code: FR00140069V2 - ALKEM). www.groupeberkem.com

¹ Limited liability company (RCS 804 788 503) with Olivier FAHY as manager.

² Simplified joint-stock company (RCS 928 791 813) with Kenercy as Chairman.



CONTACTS

Groupe Berkem

Olivier Fahy, Chairman and CEO

Anthony Labrugnas, Chief Financial Officer

Phone: +33 (0)5 64 31 06 60

investisseurs@berkem.com

NewCap

Investor Relations

Mathilde Bohin / Nicolas Fossiez

Phone: +33 (0)1 44 71 94 94

berkem@newcap.eu

NewCap

Media Relations

Nicolas Merigeau / Antoine Pacquier

Phone: +33 (0)1 44 71 94 94

berkem@newcap.eu

DISCLAIMER

This press release must not be published, broadcast or distributed, directly or indirectly, in any country in which the distribution of this information is subject to legal restrictions. Consequently, persons in the countries where this press release is released, published or distributed are required to inform themselves about and to observe any such restrictions.

This press release contains forward-looking statements that are based on reasonable assessments or assumptions as of the date of the press release, which may change or be modified as a result, in particular, of hazards or uncertainties and risks associated with the economic, financial, regulatory and competitive environment, the risks set out in the 2023 Annual Financial Report and any unknown or immaterial risks that may arise in the future. The Company undertakes to publish or communicate any corrections or updates to these items as part of the periodic and ongoing information obligation to which all listed companies are subject.